July / August #83 : Who Done It - by Mike Barr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Once Upon A Time...

Young At Heartland

The Lying Game

Life vs. Meth

This Is Only a Test

Mbeki's 180

Spin Doctors

Soda Wars

Iran Runs

New Friend

Sex Crimes

Got Milk? Get Meds

Got His Goat

Monkey C

Mind Trip

Beach Reads

Memory Lane

Face the Music

Failure Is Sweet

Who Done It

Defensive Tackle

Under the Sun

Cave Kava

Relayed Reaction

Habit Helpers

Ticked & Stoned

Rated X5

Vax Populi

TB or Not TB

IV Leader

Flower Children


Drug Interactions

Dubya Trouble

Publisher's Letter


Reed Represents

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July / August 2002

Who Done It

by Mike Barr

In April the World Health Organization (WHO) announced that, for the first time, it was adding 12 antiretrovirals to its Essential Medicines List. What took so long? There were no official guidelines for prescribing HIV meds in poor nations -- until WHO unveiled them along with the revised list. The UN agency's endorsement of HAART was timed to coincide with the first round of grants to poor countries by its Global Fund.

While the stated goal of WHO's move is to up access to HAART from the current 300,000 to 3 million by 2005, it is also expected to heighten competition for further price reductions in poor nations by "pre-qualifying" -- and even recommending -- generic manufacturers that produce the drugs. (Ten of the formulations are products of Cipla, the first company to break Western patent monopolies by offering HAART for $350 a year.) Big Pharma was notably silent on the list revision.

Three combos are identified as the simplest to start with -- a foundation of Combivir (AZT/3TC) plus either the nuke abacavir or non-nukes efavirenz or nevirapine. Protease inhibitors are recommended only after first-line failure. In a bow to reality, the new guidelines call for low-tech lab monitoring, basic blood cell counts and liver tests, allowing for treatment decisions based entirely on a person's clinical condition sans CD4-cell counts and viral load tests.

A watershed for HIV treatment worldwide, the move is also a political response to critics who argue either that the drugs don't work (think South African Prez Thabo Mbeki) or that poor people can't take them properly (think former USAID head Andrew Natsios, who wrote in a New York Times op-ed piece that Africans could never adhere to HAART because they "don't know what Western time is").

Jonathan Quick, head of WHO's essential-drugs program, said the addition "should dispel any questions about the safety, effectiveness and public-health relevance of these drugs." Yet even at $350 a year -- or $2 billion a year for all 6 million HIVers who currently need it -- HAART remains out of reach of the health budgets of most governments.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.